Guidelines for treating HIV-infected adults and post-exposure prophylaxis for HIV infection
Antiretroviral therapy represents an essential element in the approach to treatment and prevention of human immunodeficiency virus (HIV). It has changed the fatal disease to a manageable chronic condition and is the most effective prevention of its human-to-human transmission. Knowledge regarding biological characteristics of the virus, its behavior in a human host and our understanding of these phenomena have been extended by clinical experience, new clinical data and recent scientific progress. The development of new drugs becomes a modifier for the existing therapeutic strategy and preference. Certain points are more specific than in the previous guidelines. Definitions of certain clinical and laboratory conditions have been specified more accurately. The indications of specific antiretroviral agents and pitfalls of their use in lifelong antiretroviral treatment are also described more in detail. The document is a result of a general consensus among infectious disease specialists working with HIV patients in the Czech Republic. It should serve as a basic instrument for clinicians recommending treatment of HIV infection as well as a foundation for the society when dealing with both state authorities and health care payers.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Klinicka mikrobiologie a infekcni lekarstvi - 25(2019), 3 vom: 10. Sept., Seite 97-120 |
| Sprache: |
Tschechisch |
|---|
| Beteiligte Personen: |
Snopková, Svatava [VerfasserIn] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 23.01.2020 Date Revised 23.01.2020 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM305036513 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM305036513 | ||
| 003 | DE-627 | ||
| 005 | 20231225120305.0 | ||
| 007 | tu | ||
| 008 | 231225s2019 xx ||||| 00| ||cze c | ||
| 028 | 5 | 2 | |a pubmed24n1016.xml |
| 035 | |a (DE-627)NLM305036513 | ||
| 035 | |a (NLM)31904105 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a cze | ||
| 100 | 1 | |a Snopková, Svatava |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Guidelines for treating HIV-infected adults and post-exposure prophylaxis for HIV infection |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 23.01.2020 | ||
| 500 | |a Date Revised 23.01.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Antiretroviral therapy represents an essential element in the approach to treatment and prevention of human immunodeficiency virus (HIV). It has changed the fatal disease to a manageable chronic condition and is the most effective prevention of its human-to-human transmission. Knowledge regarding biological characteristics of the virus, its behavior in a human host and our understanding of these phenomena have been extended by clinical experience, new clinical data and recent scientific progress. The development of new drugs becomes a modifier for the existing therapeutic strategy and preference. Certain points are more specific than in the previous guidelines. Definitions of certain clinical and laboratory conditions have been specified more accurately. The indications of specific antiretroviral agents and pitfalls of their use in lifelong antiretroviral treatment are also described more in detail. The document is a result of a general consensus among infectious disease specialists working with HIV patients in the Czech Republic. It should serve as a basic instrument for clinicians recommending treatment of HIV infection as well as a foundation for the society when dealing with both state authorities and health care payers | ||
| 650 | 4 | |a Guideline | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Anti-Retroviral Agents |2 NLM | |
| 700 | 1 | |a Rozsypal, Hanuš |e verfasserin |4 aut | |
| 700 | 1 | |a Aster, Viktor |e verfasserin |4 aut | |
| 700 | 1 | |a Sedláček, Dalibor |e verfasserin |4 aut | |
| 700 | 1 | |a Dlouhý, Pavel |e verfasserin |4 aut | |
| 700 | 1 | |a Kapla, Jaroslav |e verfasserin |4 aut | |
| 700 | 1 | |a Jilich, David |e verfasserin |4 aut | |
| 700 | 1 | |a Veselý, Dan |e verfasserin |4 aut | |
| 700 | 1 | |a Jerhotová, Zdeňka |e verfasserin |4 aut | |
| 700 | 1 | |a Olbrechtová, Lenka |e verfasserin |4 aut | |
| 700 | 1 | |a Zjevíková, Alena |e verfasserin |4 aut | |
| 700 | 1 | |a Zlámal, Milan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Klinicka mikrobiologie a infekcni lekarstvi |d 2004 |g 25(2019), 3 vom: 10. Sept., Seite 97-120 |w (DE-627)NLM147935733 |x 1211-264X |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2019 |g number:3 |g day:10 |g month:09 |g pages:97-120 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2019 |e 3 |b 10 |c 09 |h 97-120 | ||